|Bid||1.2300 x 1000|
|Ask||1.4000 x 1100|
|Day's range||0.0200 - 0.0290|
|52-week range||0.0200 - 4.7430|
|Beta (5Y monthly)||0.04|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
NEW YORK, May 13, 2022--PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO.
NEW YORK, May 12, 2022--PAVmed provides business update and preliminary first quarter 2022 financial results.
NEW YORK, May 11, 2022--Lucid Diagnostics provides business update and preliminary first quarter 2022 financial results.